Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 7/20 | 0.51 |
| ▸ | CDK2AP1 | O14519 | 4/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4211957 | 0.97 | CHEK1 (0.54) | CHEK1CDK2AP1USP30GABRA5BTK | |
| SCHEMBL4213212 | 0.92 | CHEK1 (0.52) | CHEK1CDK2AP1USP30BTKHDAC4 | |
| SCHEMBL4706488 | 0.91 | CHEK1 (0.56) | CHEK1CDK2AP1USP30FAAH | |
| Trifluoroacetic Acid SCHEMBL4213230 | 0.88 | CHEK1 (0.65) | CHEK1CDK2AP1USP30 | |
| SCHEMBL4703475 | 0.87 | CHEK1 (0.53) | CHEK1CDK2AP1USP30FAAH | |
| SCHEMBL1562936 | 0.87 | USP30 (0.55) | CHEK1CDK2AP1USP30GABRA5BTK | |
| SCHEMBL4702699 | 0.85 | CHEK1 (0.54) | CHEK1CDK2AP1BTKFAAH | |
| SCHEMBL1563863 | 0.85 | USP30 (0.53) | CHEK1CDK2AP1USP30GABRA5BTK | |
| SCHEMBL4211373 | 0.84 | CHEK1 (0.69) | CHEK1CDK2AP1USP30PARP1 | |
| SCHEMBL13951997 | 0.83 | CHEK1 (0.44) | CHEK1CDK2AP1USP30FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1660474-B1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-20060281666-A1 | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-12-14 | — | — | US | disclosed |
| EP-1660474-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016909-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | TPMT, ABCG2, TYMP | CHEK1 297/4885CDK2AP1 2722/4885USP30 4465/4885 |
| US-20060281666-A1 | Substitute thiophenes and uses therof | TYMP, TPMT, MGMT | CHEK1 602/4885CDK2AP1 2225/4885USP30 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.